Travere Therapeutics Crushes Q2, FILSPARI Leads in IgA Nephropathy

Travere Therapeutics Q2 2025 earnings showcase FILSPARIs dominance in IgA nephropathy, with a 43% increase in new patient starts and $72M U.S. net product sales. Clinical trials highlight proteinuria reduction and stable kidney function, driving combo therapy push and FSGS SNDA on track for Jan 13, 2026. Nephrologists favor FILSPARI for rapid results, safety, and once-daily dosing, despite new competitors. Regulatory updates include REMS tweaks, and financials show improved net loss and $319M cash. Pipeline progress and partner collaborations position Travere for sustained growth in rare kidney diseases. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/48893306591e9cdd